Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02299518 · ClinicalTrials.gov registry record · Phase 1
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Alice Mims.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02299518 is a Phase 1 study that has completed, run by Alice Mims. The registered enrollment target is 23 participants.
The verdict
NCT02299518, a Phase 1 study, has completed, sponsored by Alice Mims.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of selinexor when given together with etoposide with or without mitoxantrone hydrochloride and cytarabine in treating patients with acute myeloid leukemia that has returned (relapsed) or has not responded to treatment (refractory). Selinexor may help stop the growth of tumor cells by blocking an enzyme needed for cancer cell growth. Drugs used in chemotherapy, such as etoposide, mitoxantrone hydrochloride, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy together with selinexor work better in treating relapsed or refractory acute myeloid leukemia.
Interventions
- OTHER laboratory biomarker analysis
- DRUG etoposide
- DRUG cytarabine
- DRUG mitoxantrone hydrochloride
- DRUG selinexor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-05-18 |
| Est. Completion | 2018-03-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02299518
The ClinicalTrials.gov registry entry for NCT02299518 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alice Mims, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT02299518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02299518 about?
NCT02299518 is a clinical study titled "Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". This phase I trial studies the side effects and best dose of selinexor when given together with etoposide with or without mitoxantrone hydrochloride and cytarabine in treating patients with acute myeloid leukemia that has returned (relapsed) or has not responded to treatment (refractory). Selinexor ...
What is the current status of trial NCT02299518?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2015-05-18. Estimated completion is 2018-03-06.
What interventions are being tested in trial NCT02299518?
The interventions under investigation include: laboratory biomarker analysis (OTHER), etoposide (DRUG), cytarabine (DRUG), mitoxantrone hydrochloride (DRUG), selinexor (DRUG).
Who is sponsoring clinical trial NCT02299518?
This trial is sponsored by Alice Mims, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.